214 related articles for article (PubMed ID: 19513562)
1. Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate.
Sieber S; Gdynia G; Roth W; Bonavida B; Efferth T
Int J Oncol; 2009 Jul; 35(1):149-58. PubMed ID: 19513562
[TBL] [Abstract][Full Text] [Related]
2. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis.
Vega MI; Huerta-Yepez S; Jazirehi AR; Garban H; Bonavida B
Oncogene; 2005 Dec; 24(55):8114-27. PubMed ID: 16103877
[TBL] [Abstract][Full Text] [Related]
3. Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively.
Vega MI; Jazirehi AR; Huerta-Yepez S; Bonavida B
J Immunol; 2005 Aug; 175(4):2174-83. PubMed ID: 16081784
[TBL] [Abstract][Full Text] [Related]
4. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma.
Alas S; Ng CP; Bonavida B
Clin Cancer Res; 2002 Mar; 8(3):836-45. PubMed ID: 11895917
[TBL] [Abstract][Full Text] [Related]
5. Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis.
Stel AJ; Ten Cate B; Jacobs S; Kok JW; Spierings DC; Dondorff M; Helfrich W; Kluin-Nelemans HC; de Leij LF; Withoff S; Kroesen BJ
J Immunol; 2007 Feb; 178(4):2287-95. PubMed ID: 17277134
[TBL] [Abstract][Full Text] [Related]
6. A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells.
Vega MI; Baritaki S; Huerta-Yepez S; Martinez-Paniagua MA; Bonavida B
Leuk Lymphoma; 2011 Jan; 52(1):108-21. PubMed ID: 21133714
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
8. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis.
Jazirehi AR; Gan XH; De Vos S; Emmanouilides C; Bonavida B
Mol Cancer Ther; 2003 Nov; 2(11):1183-93. PubMed ID: 14617792
[TBL] [Abstract][Full Text] [Related]
9. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis.
Suzuki E; Umezawa K; Bonavida B
Oncogene; 2007 Sep; 26(42):6184-93. PubMed ID: 17420722
[TBL] [Abstract][Full Text] [Related]
10. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
[TBL] [Abstract][Full Text] [Related]
11. What signals are generated by anti-CD20 antibody therapy?
Bonavida B
Curr Hematol Malig Rep; 2006 Dec; 1(4):205-13. PubMed ID: 20425315
[TBL] [Abstract][Full Text] [Related]
12. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.
Shan D; Ledbetter JA; Press OW
Cancer Immunol Immunother; 2000 Mar; 48(12):673-83. PubMed ID: 10752475
[TBL] [Abstract][Full Text] [Related]
13. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions.
Bonavida B
Oncogene; 2007 May; 26(25):3629-36. PubMed ID: 17530016
[TBL] [Abstract][Full Text] [Related]
14. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
15. Galiximab signals B-NHL cells and inhibits the activities of NF-κB-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugs.
Martinez-Paniagua MA; Vega MI; Huerta-Yepez S; Baritaki S; Vega GG; Hariharan K; Bonavida B
Mol Cancer Ther; 2012 Mar; 11(3):572-81. PubMed ID: 22267549
[TBL] [Abstract][Full Text] [Related]
16. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.
Jazirehi AR; Huerta-Yepez S; Cheng G; Bonavida B
Cancer Res; 2005 Jan; 65(1):264-76. PubMed ID: 15665303
[TBL] [Abstract][Full Text] [Related]
17. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.
Shimizu R; Kikuchi J; Wada T; Ozawa K; Kano Y; Furukawa Y
Leukemia; 2010 Oct; 24(10):1760-8. PubMed ID: 20686505
[TBL] [Abstract][Full Text] [Related]
18. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.
Golay J; Zaffaroni L; Vaccari T; Lazzari M; Borleri GM; Bernasconi S; Tedesco F; Rambaldi A; Introna M
Blood; 2000 Jun; 95(12):3900-8. PubMed ID: 10845926
[TBL] [Abstract][Full Text] [Related]
19. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
20. Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.
Pagel JM; Laugen C; Bonham L; Hackman RC; Hockenbery DM; Bhatt R; Hollenback D; Carew H; Singer JW; Press OW
Clin Cancer Res; 2005 Jul; 11(13):4857-66. PubMed ID: 16000584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]